Lesley A Anderson

List of Publications by Year
in descending order

89 papers	4,099 citations	117625 34 h-index	123424 61 g-index
93 all docs	93 docs citations	93 times ranked	6251 citing authors

#	Article	IF	Citations
1	Human papillomavirus related head and neck cancer survival: A systematic review and meta-analysis. Oral Oncology, 2012, 48, 1191-1201.	1.5	356
2	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnetâ€”a population-based study. Lancet Oncology, The, 2017, 18, 1022-1039.	10.7	285
3	Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncology, The, 2014, 15, 931-942.	10.7	229
4	Risk factors for Barrettâ€™s oesophagus and oesophageal adenocarcinoma: Results from the FINBAR study. World Journal of Gastroenterology, 2007, 13, 1585.	3.3	222
5	Populationâ€based study of autoimmune conditions and the risk of specific lymphoid malignancies. International Journal of Cancer, 2009, 125, 398-405.	5.1	221
6	Cigarette Smoking Increases Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology, 2012, 142, 744-753.	1.3	145
7	How common are myeloproliferative neoplasms? A systematic review and metaâ€analysis. American Journal of Hematology, 2014, 89, 581-587.	4.1	141
8	Survival for oesophageal, stomach and small intestine cancers in Europe 1999â€“2007: Results from EUROCARE-5. European Journal of Cancer, 2015, 51, 2144-2157.	2.8	138
9	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncology, The, 2016, 17, 1363-1373.	10.7	133
10	The Association Between Alcohol and Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma. Gastroenterology, 2009, 136, 799-805.	1.3	120
11	Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence. Cancer Research, 2006, 66, 4975-4982.	0.9	110
12	Oesophageal cancer survival in Europe: A EUROCARE-4 study. Cancer Epidemiology, 2012, 36, 505-512.	1.9	108
13	Hematopoietic Malignancies Associated with Viral and Alcoholic Hepatitis. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3069-3075.	2.5	100
14	Risk Factors for Classical Kaposi Sarcoma in a Population-based Case-control Study in Sicily. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3435-3443.	2.5	72
15	Determining Risk of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and GeneticÂVariants. Gastroenterology, 2018, 154, 1273-1281.e3.	1.3	67
16	Dietary fat and meat intakes and risk of reflux esophagitis, Barrett's esophagus and esophageal adenocarcinoma. International Journal of Cancer, 2011, 129, 1493-1502.	5.1	66
17	Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. American Journal of Gastroenterology, 2018, 113, 1148-1155.	0.4	57
18	Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. British Journal of Haematology, 2009, 147, 444-449.	2.5	55

#	Article	IF	Citations
19	Alcohol and the Risk of Barrett's Esophagus: A Pooled Analysis from the International BEACON Consortium. American Journal of Gastroenterology, 2014, 109, 1586-1594.	0.4	55
20	Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrettâ€™s esophagus, and esophageal adenocarcinoma. Cancer Causes and Control, 2009, 20, 279-288.	1.8	54
21	Dietary Antioxidant and Mineral Intake in Humans Is Associated with Reduced Risk of Esophageal Adenocarcinoma but Not Reflux Esophagitis or Barrett's Esophagus. Journal of Nutrition, 2010, 140, 1757-1763.	2.9	52
22	A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis, 2007, 28, 1323-1328.	2.8	49
23	Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 332-342.	2.5	48
24	Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 727-731.	2.5	46
25	Increased Risk for Lymphoid and Myeloid Neoplasms in Elderly Solid-Organ Transplant Recipients. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1229-1237.	2.5	41
26	Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2018, 16, 1229-1236.e4.	4.4	41
27	Oesophageal cancer: caregiver mental health and strain. Psycho-Oncology, 2008, 17, 1196-1201.	2.3	40
28	Genes of the Interleukin-18 Pathway Are Associated With Susceptibility to Barrett's Esophagus and Esophageal Adenocarcinoma. American Journal of Gastroenterology, 2012, 107, 1331-1341.	0.4	39
29	Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR Study. PLoS ONE, 2018, 13, e0190325.	2.5	38
30	No Association between hOGG1, XRCC1, and XPD Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, or Esophageal Adenocarcinoma: Results from the Factors Influencing the Barrett's Adenocarcinoma Relationship Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 736-739.	2.5	36
31	Vitamin D, calcium and dairy intake, and risk of oesophageal adenocarcinoma and its precursor conditions. British Journal of Nutrition, 2011, 106, 732-741.	2.3	36
32	Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiology, 2014, 38, 56-61.	1.9	36
33	Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. American Journal of Hematology, 2012, 87, 175-182.	4.1	35
34	Dietary magnesium, calcium:magnesium ratio and risk of reflux oesophagitis, Barrettâ€™s oesophagus and oesophageal adenocarcinoma: a population-based caseâ€“control study. British Journal of Nutrition, 2016, 115, 342-350.	2.3	35
35	Intakes of Dietary Folate and Other B Vitamins Are Associated with Risks of Esophageal Adenocarcinoma, Barrettâ€™s Esophagus, and Reflux Esophagitis. Journal of Nutrition, 2013, 143, 1966-1973.	2.9	33
36	Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls. American Journal of Hematology, 2015, 90, 864-870.	4.1	33

#	Article	IF	Citations
37	Age-specific risk factor profiles of adenocarcinomas of the esophagus: A pooled analysis from the international BEACON consortium. International Journal of Cancer, 2016, 138, 55-64.	5.1	31
38	Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer: a systematic review. Cancer Causes and Control, 2011, 22, 803-810.	1.8	29
39	Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2016, 111, 1528-1535.	0.4	28
40	The prevalence of viral agents in esophageal adenocarcinoma and Barrettâ€™s esophagus: a systematic review. European Journal of Gastroenterology and Hepatology, 2017, 29, 817-825.	1.6	26
41	Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the <scp>U</scp>.<scp>K</scp>. <scp>C</scp>linical <scp>P</scp>ractice <scp>R</scp>esearch <scp>D</scp>atalink. International Journal of Cancer, 2018, 142, 1174-1181.	5.1	25
42	Iron intake and markers of iron status and risk of Barrettâ€™s esophagus and esophageal adenocarcinoma. Cancer Causes and Control, 2010, 21, 2269-2279.	1.8	23
43	HPV prevalence and typeâ€distribution in cervical cancer and premalignant lesions of the cervix: A populationâ€based study from Northern Ireland. Journal of Medical Virology, 2016, 88, 1262-1270.	5.0	23
44	Association Between Aspirin Use and Biliary Tract Cancer Survival. JAMA Oncology, 2019, 5, 1802.	7.1	23
45	Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Gut, 2019, 68, 1458-1464.	12.1	23
46	Autoimmune conditions and hairy cell leukemia: an exploratory case-control study. Journal of Hematology and Oncology, 2010, 3, 35.	17.0	21
47	Dietary inflammatory index and risk of reflux oesophagitis, Barrettâ€™s oesophagus and oesophageal adenocarcinoma: a population-based caseâ€“control study. British Journal of Nutrition, 2017, 117, 1323-1331.	2.3	21
48	Have patients with esophagitis got an increased risk of adenocarcinoma? Results from a population-based study. World Journal of Gastroenterology, 2005, 11, 7290.	3.3	20
49	External Validation of the Michigan Barrettâ€™s Esophagus Prediction Tool. Clinical Gastroenterology and Hepatology, 2017, 15, 1124-1126.	4.4	19
50	Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms. HemaSphere, 2020, 4, e327.	2.7	18
51	Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2018, 16, 1598-1606.e4.	4.4	16
52	Benign tumors in myotonic dystrophy type I target diseaseâ€related cancer sites. Annals of Clinical and Translational Neurology, 2019, 6, 1510-1518.	3.7	16
53	Changing incidence of myeloproliferative neoplasms in Australia, 2003â€2014. American Journal of Hematology, 2019, 94, E107-E109.	4.1	16
54	No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clinical Gastroenterology and Hepatology, 2019, 17, 2227-2235.e1.	4.4	16

#	Article	IF	Citations
55	Sex-Specific Genetic Associations for Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2020, 159, 2065-2076.e1.	1.3	16
56	Human Herpesvirus 8 Seroprevalence Among Children and Adolescents in the United States. Pediatric Infectious Disease Journal, 2008, 27, 661-664.	2.0	15
57	Common communityâ€acquired infections and subsequent risk of multiple myeloma: A populationâ€based study. International Journal of Cancer, 2014, 134, 1734-1740.	5.1	15
58	Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. Gastroenterology, 2019, 156, 43-45.	1.3	15
59	Hepatitis C virus infection and nonâ€Hodgkin lymphoma: Interesting association or causal relationship?. International Journal of Cancer, 2008, 122, x-xii.	5.1	14
60	Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leukemia and Lymphoma, 2011, 52, 764-770.	1.3	14
61	Diabetes in relation to Barrettâ€™s esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrettâ€™s and Esophageal Adenocarcinoma Consortium. Cancer, 2019, 125, 4210-4223.	4.1	13
62	Inverse Association Between Gluteofemoral Obesity and Risk ofÂBarrettâ€™s Esophagus in a Pooled Analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 1412-1419.e3.	4.4	12
63	Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2020, 18, 2701-2709.e3.	4.4	12
64	Myeloproliferative Neoplasms: An in-Depth Case-Control (MOSAICC) Study. Blood, 2015, 126, 1621-1621.	1.4	12
65	Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma. Journal of Clinical Oncology, 2008, 26, 4958-4965.	1.6	11
66	Risk factors for Burkitt lymphoma: a nested caseâ€control study in the <scp>UK</scp> Clinical Practice Research Datalink. British Journal of Haematology, 2018, 181, 505-514.	2.5	11
67	Germline variation in the insulin-like growth factor pathway and risk of Barrettâ€™s esophagus and esophageal adenocarcinoma. Carcinogenesis, 2021, 42, 369-377.	2.8	11
68	Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications. Scandinavian Journal of Gastroenterology, 2010, 45, 1397-1403.	1.5	10
69	Supporting someone with cancer during the COVIDâ€19 pandemic: A mixed methods analysis of cancer carer's health, Quality of Life and need for support. Health and Social Care in the Community, 2022, 30, .	1.6	9
70	ERRATUM. Scandinavian Journal of Gastroenterology, 2006, 41, 247-247.	1.5	8
71	Communityâ€acquired infections associated with increased risk of lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2014, 164, 653-658.	2.5	8
72	Monoclonal gammopathy of undetermined significance as viewed by haematology healthcare professionals. European Journal of Haematology, 2018, 100, 20-26.	2.2	8

#	Article	IF	Citations
73	Risk of classic Kaposi sarcoma with exposures to plants and soils in Sicily. Infectious Agents and Cancer, 2010, 5, 23.	2.6	7
74	Using Artificial Intelligence to Revolutionise the Patient Care Pathway in Hip and Knee Arthroplasty (ARCHERY): Protocol for the Development of a Clinical Prediction Model. JMIR Research Protocols, 2022, 11, e37092.	1.0	7
75	Socioâ€economic and other correlates of Kaposi sarcomaâ€associated herpesvirus seroprevalence among older adults in Sicily. Journal of Medical Virology, 2009, 81, 1938-1944.	5.0	6
76	The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples. Annals of Human Genetics, 2018, 82, 114-118.	0.8	6
77	Patient's perspectives of living with a precancerous condition: Monoclonal gammopathy of undetermined significance (MGUS). European Journal of Oncology Nursing, 2021, 51, 101901.	2.1	6
78	Psychosocial factors and their association with reflux oesophagitis, Barrettâ€™s oesophagus and oesophageal adenocarcinoma. World Journal of Gastroenterology, 2013, 19, 1770.	3.3	6
79	A National Network of Safe Havens: Scottish Perspective. Journal of Medical Internet Research, 2022, 24, e31684.	4.3	6
80	Tumor markers and treatments for Kaposi sarcoma. Aids, 2007, 21, 1637-1639.	2.2	5
81	Patients With Barrett Esophagus Have Poor Understanding of the Diagnosis and Its Implications. Journal of Clinical Gastroenterology, 2008, 42, 431-432.	2.2	5
82	Low knowledge and awareness of monoclonal gammopathy of undetermined significance (MGUS) among general practitioners. BMC Family Practice, 2019, 20, 61.	2.9	4
83	Does Risk of Progression from Barrettâ€™s Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?. Digestive Diseases and Sciences, 2021, 66, 1965-1973.	2.3	4
84	Inverse association between gastroesophageal reflux and blood pressure: Results of a large community based study. BMC Gastroenterology, 2008, 8, 10.	2.0	3
85	Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study. Experimental Hematology and Oncology, 2015, 5, 14.	5.0	3
86	Improving Identification of Cognitive Impairment in Fragility Fracture Patients: Impact of Educational Guidelines on Current Practice. Geriatric Orthopaedic Surgery and Rehabilitation, 2020, 11, 215145932093509.	1.4	3
87	eQTL set-based association analysis identifies novel susceptibility loci for Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	1
88	Minor allele frequency of myeloproliferative neoplasm mutations in the Irish blood donor population. Hematological Oncology, 2016, 34, 161-164.	1.7	0
89	Myeloproliferative Neoplasm Patient Symptom Burden and Quality of Life: Evidence of Significant Impairment Compared to Controls Using Multivariate Analysis. Blood, 2015, 126, 1620-1620.	1.4	0